A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques
- PMID: 15315859
- DOI: 10.1016/j.vaccine.2004.03.011
A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques
Abstract
Cynomolgus macaques were immunized by either the intramuscular (i.m.) or intranasal (i.n.) route with a HIV-1 peptide-based immunogen (C4-V3 89.6P) alone, or formulated with novel adjuvants to evaluate the ability of the adjuvants to augment peptide-specific systemic and mucosal immune responses. A mutant cholera toxin, CT-E29H, or the combination of recombinant human IL-1alpha (rhIL-1alpha) protein and recombinant human GM-CSF (rhGM-CSF) protein were tested as adjuvants for i.n. immunization, while a stable emulsion of a synthetic monophosphoryl lipid A (MPL) analogue (RC529-SE) plus rhGM-CSF protein was tested as an adjuvant for i.m. immunization. Macaques immunized i.n. with peptide alone failed to elicit an anti-C4-V3 89.6P antibody response in serum. In contrast, all the tested peptide/adjuvant formulations elicited peptide-specific immune responses. RC529-SE/rhGM-CSF elicited the highest peak anti-peptide IgG geometric mean titer in serum (1:32,768 at week 25) followed by rhIL-1alpha/rhGM-CSF (1:1217 at week 10) and CT-E29H (1:256 at week 25). Measurable SHIV neutralizing antibody responses were detectable in only one macaque immunized i.m. with peptide formulated with RC529-SE/rhGM-CSF. Macaques immunized by the i.n. route with peptide in combination with CT-E29H failed to elicit measurable antibody responses at nasal or genital mucosal surfaces. In contrast, antibody responses at the nasal and genital mucosa were detected in macaques immunized by the i.n. route with peptide in combination with rhIL-1alpha/rhGM-CSF. However, antibody responses at the nasal and genital mucosa were highest in macaques immunized parenterally with peptide in combination with the adjuvants RC529-SE/rhGM-CSF. These results suggest that parenteral vaccine administration in combination with the appropriate adjuvant formulation can elicit vaccine-specific humoral immune responses in both systemic and mucosal compartments.
Similar articles
-
Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).J Immunol. 1996 Jul 1;157(1):462-72. J Immunol. 1996. PMID: 8683152
-
Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques.J Med Virol. 2007 May;79(5):474-82. doi: 10.1002/jmv.20860. J Med Virol. 2007. PMID: 17385685
-
Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.Vaccine. 2002 May 22;20(17-18):2396-403. doi: 10.1016/s0264-410x(02)00090-7. Vaccine. 2002. PMID: 12009296
-
The effect of route of immunization on mucosal immunity and protection.J Infect Dis. 1999 May;179 Suppl 3:S489-92. doi: 10.1086/314809. J Infect Dis. 1999. PMID: 10099126 Review.
-
Archaeal lipid mucosal vaccine adjuvant and delivery system.Expert Rev Vaccines. 2010 Apr;9(4):431-40. doi: 10.1586/erv.10.34. Expert Rev Vaccines. 2010. PMID: 20370552 Review.
Cited by
-
Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone ® in rhesus macaques.Vaccine. 2011 Jan 29;29(5):931-40. doi: 10.1016/j.vaccine.2010.11.024. Epub 2010 Nov 25. Vaccine. 2011. PMID: 21111777 Free PMC article.
-
Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine.PLoS One. 2008 Aug 13;3(8):e2954. doi: 10.1371/journal.pone.0002954. PLoS One. 2008. PMID: 18698426 Free PMC article.
-
Common features of mucosal and peripheral antibody responses elicited by candidate HIV-1 vaccines in rhesus monkeys.J Virol. 2014 Nov;88(22):13510-5. doi: 10.1128/JVI.02095-14. Epub 2014 Sep 10. J Virol. 2014. PMID: 25210178 Free PMC article.
-
Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments.Vaccine. 2008 Aug 18;26(35):4617-23. doi: 10.1016/j.vaccine.2008.05.084. Epub 2008 Jun 17. Vaccine. 2008. PMID: 18621451 Free PMC article. Clinical Trial.
-
Parenteral Vaccination Can Be an Effective Means of Inducing Protective Mucosal Responses.Clin Vaccine Immunol. 2016 Jun 6;23(6):438-441. doi: 10.1128/CVI.00214-16. Print 2016 Jun. Clin Vaccine Immunol. 2016. PMID: 27122485 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous